Interval breast cancers pose a significant challenge to current screening paradigms because they develop and become clinically detectable within the gaps between routine mammograms. “Interval cancers generally have a worse prognosis compared with screen-detected cancers, primarily because they are either larger or biologically more aggressive,” explains Professor Fiona J. Gilbert, a co-author and radiology professor at Cambridge. Her insights underscore the crucial need for enhanced screening methodologies that can effectively identify women at elevated risk before these cancers manifest clinically.

The study utilized a vast retrospective dataset derived from the United Kingdom’s triennial breast screening program, involving 134,217 digital mammograms performed between 2014 and 2016 across two screening centers equipped with different mammographic systems. This extensive dataset provided an ideal platform to evaluate the efficacy of AI algorithms in stratifying breast cancer risk, particularly focusing on interval cancers that standard protocols might overlook.

Central to this research was the application of Mirai, a sophisticated deep learning-based AI algorithm designed to analyze negative digital mammograms—those without evident cancer—and generate a comprehensive risk score predicting an individual’s likelihood of developing interval breast cancer within the subsequent three years. Mirai evaluates complex mammographic features, including tumor morphology and breast density, which are critical indicators that conventional risk tools often inadequately assess.

The AI model demonstrated a remarkable predictive capacity, identifying 42.4% of the 524 interval cancers within the cohort when focusing on women who scored within the highest 20% risk bracket. Specifically, among women in the top 1%, 5%, 10%, and 20% risk categories, Mirai retrospectively predicted 3.6%, 14.5%, 26.1%, and 42.4% of interval cancers, respectively. This stratification translates into a meaningful increase in cancer detection rates, effectively enabling targeted supplemental imaging interventions for the women at greatest risk.

Dr. Joshua W. D. Rothwell, the study’s lead researcher, emphasized the potential clinical implications, stating that focusing follow-up efforts on the top 20% of high-risk mammograms could identify nearly half of all interval cancers. This approach would allow for tailored supplemental imaging techniques—such as magnetic resonance imaging (MRI) or contrast-enhanced mammography—potentially revolutionizing screening schedules by shifting from a uniform triennial model to more personalized, risk-adaptive algorithms.

One notable finding was that Mirai’s predictive performance was most robust within the first year following a negative mammogram, with diminished accuracy extending into the subsequent two years. While the AI showed some limitations in women with extremely dense breast tissue—where mammographic visualization is inherently challenging—it still outperformed existing conventional risk models, highlighting AI’s promise to augment human clinical judgment.

Given the United Kingdom screens approximately 2.2 million women annually through its national breast screening program, integrating AI risk stratification could significantly optimize healthcare resources. However, logistical considerations remain paramount as calling back 20% of screened women for advanced supplemental imaging would necessitate a substantial expansion in MRI and contrast-enhanced mammography capacity, potentially impacting service delivery and cost-effectiveness.

The researchers have outlined their forthcoming objectives, which include comparative studies of commercially available AI predictive tools, detailed economic modeling, cost-effectiveness analyses, and prospective clinical trials to evaluate patient outcomes when AI-guided supplemental imaging is implemented. These efforts aim to validate and refine AI’s role in real-world screening environments, ensuring that its application improves early cancer detection without overwhelming healthcare infrastructure.

At its core, this study exemplifies the evolving complexity in breast cancer risk identification, combining multifactorial clinical data with cutting-edge machine learning technologies to illuminate subtle mammographic cues indicative of future cancer development. “Accurately identifying those women most likely to develop interval cancers while judiciously limiting unnecessary supplemental imaging is the ultimate objective,” states Professor Gilbert, underscoring the delicate balance between precision medicine and healthcare pragmatism.

This research heralds a new era where AI serves as a vital tool, enhancing radiologists’ capabilities and enabling a paradigm shift toward more dynamic, individualized breast cancer screening protocols. By integrating comprehensive mammographic analysis with predictive modeling, AI has the potential to significantly reduce diagnostic delays, improve prognoses, and ultimately save lives.

The impact of this AI-driven approach extends beyond technology, touching on important ethical, logistical, and economic considerations as healthcare systems worldwide grapple with rising cancer incidence and finite resources. Future developments will need to carefully navigate these challenges, ensuring that AI adoption enhances equity in healthcare access and outcomes without exacerbating disparities.

As AI technologies continue to mature and integrate seamlessly with clinical workflows, their role in cancer screening will likely expand, encompassing other imaging modalities and tumor types. This study represents a vital milestone in demonstrating the tangible benefits of deep learning models when applied to large-scale, real-world screening data, paving the way for broader acceptance and clinical implementation.

With the Radiological Society of North America spearheading this innovative research, the promise of AI to revolutionize breast cancer detection is becoming a reality. Continued interdisciplinary collaboration among radiologists, data scientists, healthcare policymakers, and patient advocates will be essential to fully realize AI’s transformative potential in cancer prevention and early diagnosis.

Subject of Research: People
Article Title: Evaluation of a Mammography-based Deep Learning Model for Breast Cancer Risk Prediction in a Triennial Screening Program
News Publication Date: 28-Oct-2025
Web References: https://pubs.rsna.org/journal/radiology, https://www.rsna.org/
References: Gilbert F.J., Rothwell J.W.D., et al. “Evaluation of a Mammography-based Deep Learning Model for Breast Cancer Risk Prediction in a Triennial Screening Program,” Radiology, 2025.
Keywords: Breast cancer, Artificial intelligence, Mammography

TNBC is notoriously difficult to detect and treat due to its significant heterogeneity. Unlike breast cancers driven primarily by hormone receptors or HER2 expression, TNBC encompasses a complex array of molecular subtypes, each with distinct characteristics and clinical outcomes. This diversity complicates the development of universal diagnostic markers and targeted therapies. Noninvasive imaging techniques capable of accurately identifying and characterizing the wide spectrum of TNBC tumors remain elusive, severely limiting precision medicine approaches for these patients.

In response to this challenge, a team led by experts at Memorial Sloan Kettering Cancer Center devised an innovative strategy centered on the tumor microenvironment rather than tumor cell markers alone. They focused on extra domain A of fibronectin (EDA-FN), a splice variant of the fibronectin protein abundantly and stably expressed within the extracellular matrix of many aggressive tumors, including TNBC. The consistent presence of EDA-FN in the tumor stroma across diverse subtypes makes it an attractive target to circumvent the heterogeneity that stymies conventional markers.

The researchers engineered a monoclonal antibody-based radiotracer, designated [^89Zr]Zr-DFO-F8, designed to selectively bind EDA-FN. By labeling this antibody with Zirconium-89, a positron-emitting isotope suitable for PET imaging, the team created a tracer capable of delivering high-resolution, quantitative images of EDA-FN distribution in vivo. This molecular imaging agent was rigorously evaluated through a series of in vitro assays and preclinical in vivo models that represent multiple TNBC subtypes, assessing its specificity, binding affinity, and tumor uptake.

In vitro studies confirmed the high specificity and blockable binding of [^89Zr]Zr-DFO-F8 to EDA-FN, demonstrating that the tracer interacts precisely with its intended target without significant off-target effects. Subsequently, in vivo experiments utilizing various xenograft models implanted subcutaneously and orthotopically within murine hosts revealed robust accumulation of the tracer within tumors expressing elevated levels of EDA-FN. Notably, tracer uptake correlated strongly with the degree of EDA-FN expression and tumor aggressiveness, underscoring its utility as a marker of malignant potential.

This imaging modality transcends traditional tumor cell–centric approaches by exploiting the tumor’s extracellular matrix, thereby bypassing the variability of surface markers inherent to tumor cells themselves. The results herald a paradigm shift in the nuclear medicine field, positioning extracellular matrix components as reliable, broadly applicable targets for cancer imaging. Consequently, [^89Zr]Zr-DFO-F8 has the potential not only to detect TNBC earlier and more accurately but also to guide precision therapy by identifying patients who might benefit from stromal-targeted treatments or monitoring therapeutic efficacy dynamically.

“This approach represents a significant stride toward overcoming the tumor heterogeneity that has impeded effective imaging in triple-negative breast cancer,” remarked Dr. Jason Lewis, the study’s senior investigator. “By focusing on a stable, abundant extracellular protein like EDA-FN, we open avenues for more universal diagnostic tools that can address the diversity and complexity of TNBC,” Lewis explained. The tracer’s ability to visualize tumor microenvironment components rather than relying solely on tumor cells broadens the applicability of such imaging agents across a spectrum of hard-to-target cancers.

Beyond diagnostic applications, the [^89Zr]Zr-DFO-F8 tracer may facilitate personalized treatment planning. Imaging results can inform clinicians about tumor invasiveness and stromal composition, essential parameters that influence therapeutic responses. By enabling longitudinal monitoring of tumor microenvironment alterations during treatment, this imaging technique provides a noninvasive means to evaluate effectiveness and adapt regimens in real time, arguably enhancing patient outcomes and fostering more rationalized clinical decisions.

The research team employed several preclinical TNBC models to comprehensively validate their tracer. These models encompassed diverse molecular profiles, ensuring that the imaging agent’s utility would not be limited to a narrow subset of TNBC. Remarkably, EDA-FN targeting by [^89Zr]Zr-DFO-F8 succeeded across all tested models, highlighting the robust and ubiquitous nature of this extracellular matrix marker. Such broad-spectrum applicability is a critical feature enabling this technology to have widespread clinical influence.

While many current molecular imaging probes target tumor-specific receptors or antigens, issues with variable expression and rapid mutation limit their long-term clinical utility, particularly in heterogeneous diseases like TNBC. [^89Zr]Zr-DFO-F8 circumvents these challenges by homing in on stromal proteins that are less prone to genetic alterations and provide a stable target environment. This strategy aligns with the evolving appreciation of the tumor microenvironment’s role in cancer progression and resistance, offering new vistas for theranostic development.

Looking ahead, ongoing work aims to translate these promising findings into human clinical trials. Critical questions remain regarding tracer pharmacokinetics, dosimetry, safety profiles, and imaging protocols. Nevertheless, the preclinical data position [^89Zr]Zr-DFO-F8 as a frontrunner in the quest for universal TNBC imaging agents. The successful clinical implementation of this technology could substantially improve the landscape for one of the most difficult breast cancer subtypes, ultimately enhancing survival and quality of life for patients worldwide.

This research exemplifies the power of multidisciplinary collaboration, integrating molecular biology, radiochemistry, and nuclear medicine in a concerted effort to address unmet clinical needs. Partnering with industry experts, including those from Philochem AG and Philogen Group, the investigators have leveraged antibody engineering and radiolabeling expertise to develop a state-of-the-art tracer that marries specificity with translational potential. Such synergies highlight how innovation at the intersection of science and technology can accelerate impactful advances in cancer care.

In sum, the development of [^89Zr]Zr-DFO-F8 as a PET imaging agent targeting the extracellular matrix protein EDA-FN heralds a new era in triple-negative breast cancer detection and management. By sidestepping the limitations imposed by tumor heterogeneity and focusing on the tumor microenvironment, this approach provides a compelling pathway to improved diagnosis, treatment planning, and monitoring. As the fight against TNBC intensifies, molecular imaging innovations like this offer hope for more effective, personalized interventions that can ultimately save lives.

Subject of Research: Targeting Extra Domain A of Fibronectin for molecular imaging of triple-negative breast cancer

Article Title: Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer

News Publication Date: June 4, 2025

Web References:

• Journal of Nuclear Medicine Article
• JNM Website
• Journal of Nuclear Medicine Twitter
• Journal of Nuclear Medicine Facebook
• Journal of Nuclear Medicine LinkedIn

Image Credits: Images created by Justin S. Hachey, Memorial Sloan Kettering Cancer Center, New York, NY.

Keywords: Molecular imaging, breast cancer, triple-negative breast cancer, positron emission tomography, extracellular matrix, fibronectin, tumor heterogeneity, PET tracer, EDA-FN, zirconium-89, monoclonal antibody, tumor microenvironment